Cargando…
Capturing seizures in clinical trials of antiseizure medications for KCNQ2‐DEE
Literature review of patients with KCNQ2 developmental and epileptic encephalopathy (KCNQ2‐DEE) reveals, based on 16 reports including 139 patients, a clinical phenotype that includes age‐ and disease‐specific stereotyped seizures. The typical seizure type of KCNQ2‐DEE, focal tonic, starts within 0‐...
Autores principales: | Millichap, John J., Harden, Cynthia L., Dlugos, Dennis J., French, Jacqueline A., Butterfield, Noam N., Grayson, Celene, Aycardi, Ernesto, Pimstone, Simon N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918316/ https://www.ncbi.nlm.nih.gov/pubmed/33681646 http://dx.doi.org/10.1002/epi4.12466 |
Ejemplares similares
-
KCNQ2‐DEE: developmental or epileptic encephalopathy?
por: Berg, Anne T., et al.
Publicado: (2021) -
Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years
por: French, Jacqueline A., et al.
Publicado: (2022) -
Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial
por: French, Jacqueline A., et al.
Publicado: (2023) -
Antiseizure medication discovery: Recent and future paradigm shifts
por: Talevi, Alan
Publicado: (2022) -
Mouse models of Kcnq2 dysfunction
por: Brun, Lucile, et al.
Publicado: (2022)